Publications Database

Good P. (2006)

Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause?

Medical Hypotheses

67(3), pp. 671-672

Gringras P. (2000)

Practical paediatric psychopharmacological prescribing in autism: the potential and the pitfalls.

Autism

4(3), pp. 229-247

Read Abstract (New Window)

Herman B. (1993)

Cardiovascular and other physical effects of acute administration of naltrexone in autistic children.

Journal of Child and Adolescent Psychopharmacology

3(3), pp. 157-168

Herman B. et al. (1989)

Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children.

Developmental Pharmacology

12(3), pp. 118-127

Read Abstract (New Window)

Knabe R. , Schultz P. , Richard J. (1990)

Initial aggravation of self-injurious behavior in autistic patients receiving naltrexone treatment.

Journal of Autism and Developmental Disorders

20(4), pp. 591-593

Read Extract (New Window)

Kolmen B. K. et al. (1995)

Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.

Journal of the American Academy of Child and Adolescent Psychiatry

34(2), pp. 223-231

Read Abstract (New Window)

Kolmen B. K. et al. (1997)

Naltrexone in young autistic children: replication study and learning measures.

Journal of the American Academy of Child and Adolescent Psychiatry

36(11), pp. 1570-1578

Read Abstract (New Window)

Leboyer M. et al. (1992)

Brief report: a double-blind study of naltrexone in infantile autism.

Journal of Autism and Developmental Disorders

22(2), pp. 309-319

Leboyer M. , Bouvard M. P. , Dugas M. (1998)

Effects of naltrexone on infantile autism.

Lancet

1(8587), p. 715

Lee Y. J. et al. (2014)

Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.

Clinical Psychopharmacology and Neuroscience

Read Abstract (New Window) Read Full (New Window)

Lensing P. et al. (1995)

Clinical case report opiate antagonist and event-related desynchronization in 2 autistic boys.

Neuropsychobiology

31(1), pp. 16-23

Read Abstract (New Window)

Lensing P. et al. (1992)

Naltrexone open trial with a 5-year-old-boy. A social rebound reaction.

Acta Paedopsychiatrica

55(3), pp. 169-173

Read Abstract (New Window)

Masi G. (2004)

Pharmacotherapy of pervasive developmental disorders in children and adolescents.

CNS Drugs

18(14), pp. 1031-1052

Read Abstract (New Window)

Panksepp J. , Lensing P. (1991)

A synopsis of an open-trial of naltrexone treatment of autism with four children.

Journal of Autism and Developmental Disorders

21(2), pp. 243-249

Read Abstract (New Window)

Parikh M. , Kolevzon A. , Hollander E. (2008)

Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability

Journal of Child and Adolescent Psychopharmacology

April, 18(2), pp. 157-178

Read Abstract (New Window)

American Society of Health-System Pharmacists (2009)

Naltrexone.

Bethesda, MD: American Society of Health-System Pharmacists

Read Full (New Window)

Posey D. J. , McDougle C. J. (2000)

The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders.

Harvard Review of Psychiatry

8(2), pp. 45-63

Read Abstract (New Window)

Rana F. , Gormez A. , Varghese S. (2013)

Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities.

Cochrane Database of Systematic Reviews

30(4),

Read Abstract (New Window) Read Full (New Window)

Rapp J. T. , Vollmer T. R. (2005)

Stereotypy II: a review of neurobiological interpretations and suggestions for an integration with behavioral methods.

Research in Developmental Disabilities

26(6), pp. 548-564

Read Abstract (New Window)

Riddle M. A. et al. (1999)

Anxiolytics, adrenergic agents, and naltrexone.

Journal of the American Academy of Child and Adolescent Psychiatry

38(5), pp. 546-556

Read Abstract (New Window)